Evidence map›Paper›PMID 35840578›Full record

ArticleNature communications2022

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.

Ian D Ferguson, Bonell Patiño-Escobar, Sami T Tuomivaara, Yu-Hsiu T Lin, Matthew A Nix, Kevin K Leung, Corynn Kasap, Emilio Ramos, Wilson Nieves Vasquez, Alexis Talbot and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 125 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Emerging roles of RNA mInternational journal of oncology · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 8 institutions in 3 countries.

Ian D FergusonDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Bonell Patiño-EscobarDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0003-2622-4822
Sami T TuomivaaraDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0002-7150-0665
Yu-Hsiu T LinDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0002-7157-4330
Matthew A NixDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Kevin K LeungDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID 0000-0002-2087-4974
Corynn KasapDepartment of Medicine, Division of Hematology/Oncology, University of California, San Francisco, CA, USA.
Emilio RamosDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Wilson Nieves VasquezDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.ORCID 0000-0003-0423-4472
Alexis TalbotDepartment of Medicine, Division of Hematology/Oncology, University of California, San Francisco, CA, USA.ORCID 0000-0001-6734-413X
Martina HaleDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Akul NaikDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Audrey KishishitaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Priya ChoudhryDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Antonia Lopez-GironaBristol Myers Squibb/Celgene, San Diego, CA, USA.
Weili MiaoProgram in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-7487-8962
Sandy W WongDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Jeffrey L WolfDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Thomas G MartinDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Nina ShahDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Scott VandenbergDepartment of Pathology, University of California, San Francisco, CA, USA.
Sonam PrakashDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Lenka BesseDepartment of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Christoph DriessenDepartment of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Avery D PoseyDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.ORCID 0000-0001-8711-629X
R Dyche MullinsDepartment of Medicine, Division of Hematology/Oncology, University of California, San Francisco, CA, USA.ORCID 0000-0002-0871-5479
Justin EyquemDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID 0000-0001-8262-1190
James A WellsDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID 0000-0001-8267-5519
Arun P WiitaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA. arun.wiita@ucsf.edu.ORCID 0000-0002-7465-6964
University of California, San Francisco · USKantonsspital St. Gallen · CHBristol-Myers Squibb (United States) · USGladstone Institutes · USHoward Hughes Medical Institute · USInserm · FRStanford University · USTranslational Therapeutics (United States) · US

Funding

Molecular Chaperones and Small MoleculesR01NS059690 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jason E Gestwicki · 2008 to 2026
$7.9M
Renewable antibodies to secreted proteins and single and multi-pass cell surfaceP41CA196276 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARKS, JAMES D. · 2014 to 2018
$5.8M
Surfaceomic technologies and antibodies to probe cell surface proteomes and their interactomes at unprecedented small scale and high-resolutionR35GM122451 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAMES A WELLS · 2017 to 2026
$5.3M
Assembly and function of cytoskeletal systems in eukaryotic and prokaryoticcellsR35GM118119 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MULLINS, R DYCHE · 2016 to 2025
$4.8M
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacyR01CA226851 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2018 to 2022
$1.6M
BLRD VA IK2 BX004183Howard Hughes Medical InstituteNCI NIH HHS P41 CA196276NCI NIH HHS R01 CA226851NIGMS NIH HHS R35 GM118119NIGMS NIH HHS R35 GM122451NINDS NIH HHS R01 NS059690
6 · The paper itself

Abstract

The myeloma surface proteome (surfaceome) determines tumor interaction with the microenvironment and serves as an emerging arena for therapeutic development. Here, we use glycoprotein capture proteomics to define the myeloma surfaceome at baseline, in drug resistance, and in response to acute drug treatment. We provide a scoring system for surface antigens and identify CCR10 as a promising target in this disease expressed widely on malignant plasma cells. We engineer proof-of-principle chimeric antigen receptor (CAR) T-cells targeting CCR10 using its natural ligand CCL27. In myeloma models we identify proteins that could serve as markers of resistance to bortezomib and lenalidomide, including CD53, CD10, EVI2B, and CD33. We find that acute lenalidomide treatment increases activity of MUC1-targeting CAR-T cells through antigen upregulation. Finally, we develop a miniaturized surface proteomic protocol for profiling primary plasma cell samples with low inputs. These approaches and datasets may contribute to the biological, therapeutic, and diagnostic understanding of myeloma.

Indexed as

Multiple MyelomaDrug ResistanceHumansImmunotherapyLenalidomideProteomicsTumor MicroenvironmentLenalidomide

Identifiers

PMID35840578
PMCPMC9287322
OpenAlexW4285493547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.